Articles and Videos
The Dales Report: InMed Pharmaceuticals: Commercializing The Development Of Rare Cannabinoids For The Wellness Market
Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, about the rare cannabinoid market and being able to manufacture rare cannabinoids like...
Edison: Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids
InMed featured in this article about the different cannabinoid manufacturing technologies that are shaping the industry. The article by Edison also talks about the cannabinoid...
Fly exclusive interview with CEO Eric Adams
Leading digital financial news publisher "The Fly" gets an update on the launch of InMed's rare cannabinoid products and progress of our programs from CEO Eric A....
Empowered Patient Podcast: Manufacturing Bioidentical Rare Cannabinoids to Treat Glaucoma and Rare Skin Disease with Eric Adams InMed Pharmaceuticals
Empowered Patient Podcast Host Karen Jagoda speaks with InMed CEO Eric A. Adams about the company's cannabinol programs in glaucoma and epidermolysis bullosa. Excerpt: Eric...
Fireside Chat with Roth Capital: InMed’s CEO, Eric A. Adams Sits Down with Roth Analyst Scott Henry
At the 2022 Roth Conference in California, InMed's CEO, Eric A. Adams, sat down with Roth Capital Analyst Scott R. Henry in a fireside chat....
Forbes Health: What is CBN?
Forbes reporter Lauren Silva dives into the science behind rare cannabinoid, cannabinol, also known as CBN. The article features clinical and preclinical research conducted on...
